Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 2

2(40.0%)

Phase 3

1(20.0%)

5Total

N/A(2)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT04166656Phase 3Recruiting

Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.

Role: collaborator

NCT03069703Phase 2Completed

Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy

Role: collaborator

NCT03873727Phase 2Unknown

Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients.

Role: collaborator

NCT04208711Not ApplicableUnknown

Role of PLA2G1B During HIV Infection

Role: collaborator

NCT00908557Not ApplicableCompleted

Impact of Readability Improvements on the Comprehension of Written Information Given to Clinical Trial Patients: a RCT

Role: collaborator

All 5 trials loaded